key: cord-0736402-adx71l7e
authors: Nagai, Kei; Kageyama, Mikiko; Iwase, Mamiko; Ueda, Atsushi
title: A young adult with nephrotic syndrome following COVID-19 vaccination
date: 2022-01-04
journal: CEN Case Rep
DOI: 10.1007/s13730-021-00673-z
sha: e55cde921600e06178716bd87bef949be7b4cbd2
doc_id: 736402
cord_uid: adx71l7e

nan

was immediately hospitalized and given intravenous heparin because of a coagulation abnormality (fibrinogen 812 mg/ dL). After hospitalization, he was treated with an oral prednisolone 1 mg/kg/day and furosemide 40 mg intravenously. Fortunately, he did not have renal dysfunction, and improvement of edema appeared on the second day of admission. The clinical signs of NS improved steadily, and urinary protein had completely disappeared on the seventh day. On the 17th day, he was transferred to another hospital, because he wanted treatment at a medical institution near his residence.

Establishing herd immunity against COVID-19 is a pressing need for controlling the pandemic. Therefore, we recognize that a realistic path to population immunity is vaccination of a wide range of age groups. Exactly how the immune response induced by the vaccine will improve the pathophysiology of COVID-19 remains unknown [2] . COVID-19 vaccination induces various immunological reactions, particularly a Th1-dominant response [3] , which may induce glomerular disease including nephrotic syndrome [4] . However, there is no direct evidence for causality linking COVID-19 vaccination and MCNS in the present case and others [1] .

Nevertheless, we should be careful not to overlook newly developed proteinuria and edema, as well as common side effects due to vaccination, in young adults to elderly persons. Moreover, whether the second dose of vaccination should be given in such cases remains a question.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Fig. 1 Clinical course. Sixteen days before admission, the patient receives the first dose of the COVID-19 vaccine. He develops local muscle pain without systemic symptoms for 1 week, but it is self-limited. Subsequently, facial edema, leg edema, and weight gain occur. On visiting our hospital, he is diagnosed with newly developed nephrotic syndrome (NS) and treated with prednisolone, heparin, and diuretics. Clinical signs of NS improve steadily, and urinary protein disappears completely on the seventh day Prednisolone 60 mg 50 mg 

New-onset pediatric nephrotic syndrome following Pfizer-BioNTech SARS-CoV-2 vaccination: a case report and literature review

COVID-19 and immunity: quo vadis?

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome

The authors would like to thank Satoshi Hara and Takumi Kurita for their clinical support.

Informed consent Informed consent for publication was obtained from the patient described in this report.